IN THE CLAIMS:

1. (Withdrawn) Compounds of formula I :



I

wherein

R^1 = H, or C_1-C_{20} alkyl, cycloalkyl, alkenyl, aryl, arylalkyl, or alkylaryl, =CHR^3, -$C(O)OR^3$, -$C(O)R^3$,-$CH_2C(O)OR^3$, -$CH_2C(O)NHR^3$, where R^3 is H or C_1-C_{10} alkyl, cycloalkyl, or alkenyl;

R^2 = C_1-C_{20} alkyl, cycloalkyl, alkenyl, aryl, arylalkyl, or alkylaryl;

X^1 = NHR^4, where R^4 is H, C_1-C_{20} alkyl, cycloalkyl, alkenyl, aryl, arylalkyl, or alkylaryl, the R^4 group optionally containing a carbonyl group, a carboxyl group, a carboxyamide group, an alcohol group, or an ether group, the R^4 group further optionally containing one or more halogen atoms.

2. (Withdrawn) The compounds of claim 1, wherein R^1 is H, or C_1-C_{10} alkyl, cycloalkyl, alkenyl, aryl, arylalkyl, or alkylaryl, or =CH_2.

3. (Withdrawn) The compounds of claim 2, wherein R^1 is -CH_3 or =CH_2.

4. (Withdrawn) The compounds of claim 3, wherein the compound is selected from the group consisting of:

		
		 , and
		

5. (Withdrawn) The compounds of claim 1, wherein R^4 is $-CH_2C(O)OR^5$ or $-CH_2C(O)NHR^5$, where R^5 is H, C_1-C_{10} alkyl, cycloalkyl, alkenyl, aryl, arylalkyl, or alkylaryl.

6. (Withdrawn) The compounds of claim 1, wherein the compound is selected from the group consisting of:

	 , and	

7. (Withdrawn) Compounds of formula II:



II

wherein

R^6 = H, or C_1-C_{20} alkyl, cycloalkyl, alkenyl, aryl, arylalkyl, or alkylaryl, -C(O)OR^8, -C(O)R^8, -CH_2C(O)OR^8, -CH_2C(O)NHR^8, where R^8 is H or C_1-C_{10} alkyl, cycloalkyl, or alkenyl;

R^7 = C_1-C_{20} alkyl, cycloalkyl, alkenyl, aryl, arylalkyl, or alkylaryl;

X^2 = NHR^9, where R^9 is H, C_1-C_{20} alkyl, cycloalkyl, alkenyl, aryl, arylalkyl, or alkylaryl, the R^9 group optionally containing a carbonyl group, a carboxyl group, a carboxyamide group, an alcohol group, or an ether group, the R^9 group further optionally containing one or more halogen atoms;

with the proviso that when R^6 is-CH_3, and R^7 is n-$C_{13}H_{27}$, X^2 is not -NHC_2H_5.

8. (Withdrawn) The compounds of claim 7, wherein R^6 is C_1-C_{10} alkyl, cycloalkyl, alkenyl, aryl, arylalkyl, or alkylaryl.

9. (Withdrawn) The compounds of claim 8, wherein R^6 is -CH_3.

10. (Withdrawn) The compounds of claim 7, wherein R^9 is-CH_2C(O)OR^{10} or-CH_2C(O)NHR^{10}, where R^{10} is H, C_1-C_{10} alkyl, cycloalkyl, alkenyl, aryl, arylalkyl, or alkylaryl.

11. (Withdrawn) Compounds of formula IV:



IV

wherein

R^{16} = H, or C_1-C_{20} alkyl, cycloalkyl, alkenyl, aryl, arylalkyl, or alkylaryl,-$C(O)OR^{18}$, -$C(O)R^{18}$, -$CH_2C(O)OR^{18}$, -$CH_2C(O)NHR^{18}$, where R^{18} is H or C_1-C_{10} alkyl, cycloalkyl, or alkenyl;

R^{17} = C_1-C_{20} alkyl, cycloalkyl, alkenyl, aryl, arylalkyl, or alkylaryl;

X^4 = OR^{19}, where R^{19} is C_1-C_{20} alkyl, cycloalkyl, alkenyl, aryl, arylalkyl, or alkylaryl, the R^{19} group optionally containing a carbonyl group, a carboxyl group, a carboxyamide group, an alcohol group, or an ether group, the R^{19} group further optionally containing one or more halogen atoms;

with the proviso that when R^{16} is -CH_3 and R^{19} is -CH_3, then R^{17} is not substituted or unsubstituted phenyl, -nC_3H_7, -nC_5H_{11}, -$nC_{13}H_{27}$, and with the further proviso that when R^{16} is H and R^{19} is -CH_3, then R^{17} is not substituted or unsubstuted phenyl or -CH_3, and when R^{16} is H and R^{19} is -CH_2CH_3, then R^{17} is not -iC_3H_7, or substituted or unsubstituted phenyl.

12. (Withdrawn) The compounds of claim 11, wherein R^{16} is C_1-C_{10} alkyl, cycloalkyl, alkenyl, aryl, arylalkyl, or alkylaryl.

13. (Withdrawn) The compounds of claim 12, wherein R^{16} is -CH_3.

14. (Withdrawn) The compounds of claim 11, wherein R^{19} is -$CH_2C(O)OR^{20}$ or -$CH_2C(O)NHR^{20}$, where R^{20} is C_1-C_{20} alkyl, cycloalkyl, alkenyl, aryl, arylalkyl, or alkylaryl.

15. (Currently Amended) Compounds of formula V:



V

wherein

R^{21} = ~~C_2-C_{20} alkyl~~, cycloalkyl, alkenyl, aryl, arylalkyl, or alkylaryl, $=CHR^{23}$, $-C(O)OR^{23}$ $-C(O)R^{23}$, $-CH_2C(O)OR^{23}$, $-CH_2C(O)NHR^{23}$, where R^{23} is H or C_1-C_{10} alkyl, cycloalkyl, or alkenyl, except when R^{21} is $=CHR^{23}$, R^{23} is not H;

R^{22} = C_2-C_{20} alkyl, cycloalkyl, alkenyl, ~~aryl,~~ arylalkyl, or alkylaryl;

with the proviso that when R^{21} is -COOH, then R^{22} is not $-CH_3$, $-nC_5H_{11}$, or $C_{13}H_{27}$ and with the further proviso that when R^{21} is $-CH_2COOH$, then R^{22} is not $-CH_2CH_3$, or $-iC_5H_{11}$.

16. (Currently Amended) The compounds of claim 1 5, wherein R^{21} is ~~C_2-C_{20} alkyl,~~ cycloalkyl, alkenyl, aryl, arylalkyl, or alkylaryl.

17. (Cancelled)

18. (Withdrawn) Compounds of formula VI:



VI

wherein:

R^{24} = C_2-C_{20} alkyl, cycloalkyl, alkenyl, aryl, arylalkyl, or alkylaryl, -C(O)OR^{26}, -C(O)R^{26}, - $CH_2C(O)OR^{26}$, -$CH_2C(O)NHR^{26}$, where R^{26} is H or C_1-C_{10} alkyl, cycloalkyl, or alkenyl;

R^{25} = C_1-C_{20} alkyl, cycloalkyl, alkenyl, aryl, arylalkyl, or alkylaryl;

with the proviso that when R^{24} is -COOH, then R^{25} is not -CH_3, -nC_5H_{11}, or $C_{13}H_{27}$, and with the further proviso that when R^{24} is-CH_2COOH, then R^{25} is not-CH_3,-CH_2CH_3, or – iC_5H_{11}.

19. (Withdrawn) The compounds of claim 18, wherein R^{21} is C_2-C_{10} alkyl, cycloalkyl, alkenyl, aryl, arylalkyl, or alkylaryl.

20. (Currently Amended) Compounds of formula VII:



VII

wherein

R^{27} = ~~C_{12} alkyl, C_{14} alkyl,~~ C_{16}-C_{20} alkyl.

21 – 22. (Cancelled)

23. (Withdrawn) A pharmaceutical composition comprising a pharmaceutical diluent and a compound of formula IX:



IX

R^{29} = H, or C_1-C_{20} alkyl, cycloalkyl, alkenyl, aryl, arylalkyl, or alkylaryl, $=CHR^{31}$, $-C(O)OR^{31}$,- $C(O)R^{31}$,$-CH_2C(O)OR^{31}$, $-CH_2C(O)NHR^{31}$, where R^{31} is H or C_1-C_{10} alkyl, cycloalkyl, or alkenyl;

R^{30} = C_1-C_{20} alkyl, cycloalkyl, alkenyl, aryl, arylalkyl, or alkylaryl;

X^5 = $-OR^{32}$, or $-NHR^{32}$, where R^{32} is H, C_1-C_{20} alkyl, cycloalkyl, alkenyl, aryl, arylalkyl, or alkylaryl, the R^{32} group optionally containing a carbonyl group, a carboxyl group, a carboxyamide group, an alcohol group, or an ether group, the R^{32} group further optionally containing one or more halogen atoms;

with the proviso that when R^{29} is $=CH_2$, then X^5 is not OH.

24. (Withdrawn) The pharmaceutical compositions of claim 23, wherein R^{29} is C_1-C_{10} alkyl, cycloalkyl, alkenyl, aryl, arylalkyl, or alkylaryl, or $=CH_2$.

25. (Withdrawn) The pharmaceutical compositions of claim 24, wherein R^{29} is $-CH_3$ or $=CH_2$.

26. (Withdrawn) The pharmaceutical compositions of claim 23, wherein R^{32} is $-CH_2C(O)OR^{33}$ or- $CH_2C(O)NHR^{33}$, where R^{33} is C_1-C_{10} alkyl, cycloalkyl, alkenyl, aryl, arylalkyl, or alkylaryl.

27. (Withdrawn) The pharmaceutical compositions of claim 23, where R^{29} is $-C_6H_{13}$ or $-C_8H_{17}$.

28. (Withdrawn) The pharmaceutical compositions of claim 23, wherein the compound is selected from the group consisting of:



29. (Withdrawn) A pharmaceutical composition comprising a pharmaceutical diluent and a compound according to claim 1.

30. (Withdrawn) A pharmaceutical composition comprising a pharmaceutical diluent and a compound according to claim 7.

31. (Withdrawn) A pharmaceutical composition comprising a pharmaceutical diluent and a compound according to claim 11.

32. (Original) A pharmaceutical composition comprising a pharmaceutical diluent and a compound according to claim 15.

33. (Withdrawn) A pharmaceutical composition comprising a pharmaceutical diluent and a compound according to claim 18.

34. (Original) A pharmaceutical composition comprising a pharmaceutical diluent and a compound according to claim 20.

35. (Withdrawn) A pharmaceutical composition comprising a pharmaceutical diluent and a compound according to claim 22.

36. (Withdrawn) A pharmaceutical composition comprising a pharmaceutical diluent and a compound according to Formula III:



III

wherein

R^{11} = H, or C_1-C_{20} alkyl, cycloalkyl, alkenyl, aryl, arylalkyl, or alkylaryl, $=CHR^{13}$, $-C(O)OR^{13}$,- $C(O)R^{13}$, $-CH_2C(O)OR^{13}$, $-CH_2C(O)NHR^{13}$, where R^{13} is H or C_1-C_{10} alkyl, cycloalkyl, or alkenyl;

R^{12} = C_1-C_{20} alkyl, cycloalkyl, alkenyl, aryl, arylalkyl, or alkylaryl ;

$X^3 = OR^{14}$, where R^{14} is C_1-C_{20} alkyl, cycloalkyl, alkenyl, aryl, arylalkyl, or alkylaryl, the R^{14} group optionally containing a carbonyl group, a carboxyl group, a carboxyamide group, an alcohol group, or an ether group, the R^{14} group further optionally containing one or more halogen atoms.

37. (Withdrawn) The pharmaceutical formulation of claim 36, wherein R^{11} is C_1-C_{10} alkyl, cycloalkyl, alkenyl, aryl, arylalkyl, or alkylaryl, or $=CH_2$.

38. (Withdrawn) The pharmaceutical formulation of claim 37, wherein R^{11} is $-CH_3$ or $=CH_2$.

39. (Withdrawn) The pharmaceutical formulation of claim 36, wherein R^{14} is $-CH_2C(O)OR^{15}$ or $CH_2C(O)NHR^{15}$, where R^{15} is C_1-C_{10} alkyl, cycloalkyl, alkenyl, aryl, arylalkyl, or alkylaryl.

40. (Withdrawn) A method of inducing weight loss in an animal or human subject comprising administering an effective amount of a pharmaceutical composition according to claim 23 to said subject.

41. (Withdrawn) The method of claim 40, wherein the subject is a human.

42. (Withdrawn) The method of claim 40, wherein the subject is an animal.

43. (Withdrawn) The method of claim 41, wherein the pharmaceutical composition comprises a compound selected from the group consisting of



, and

44. (Withdrawn) The method of claim 42, wherein the pharmaceutical composition comprises a compound selected from the group consisting of:



45. (Withdrawn) A method of inhibiting growth of cancer cells in an animal or human subject, comprising administering an effective amount of a pharmaceutical composition according to claim 23 to said subject.

46. (Withdrawn) The method of claim 45, wherein the subject is a human.

47. (Withdrawn) The method of claim 45, wherein the subject is an animal.

48. (Withdrawn) The method of claim 46, wherein the pharmaceutical composition comprises a compound selected from the group consisting of



49. (Withdrawn) The method of claim 47, wherein the pharmaceutical composition comprises a compound selected from the group consisting of:



50. (Withdrawn) A method of stimulating the activity of CPT-1 in an animal or human subject comprising administering an effective amount of a pharmaceutical composition according to claim 23 to said subject.

51. (Withdrawn) The method of claim 50, wherein the subject is a human.

52. (Withdrawn) The method of claim 50, wherein the subject is an animal.

53. (Withdrawn) The method of claim 51, wherein the compound is:



54. (Withdrawn) The method of claim 52, wherein the compound is:



55. (Withdrawn) A method of inhibiting the activity of neuropeptide-Y in an animal or human subject comprising administering an effective amount of a pharmaceutical composition according to claim 23 to said subject.

56. (Withdrawn) The method of claim 55, wherein the subject is a human.

57. (Withdrawn) The method of claim 55, wherein the subject is an animal.

58. (Withdrawn) A method of inhibiting fatty acid synthase activity in an animal or human subject comprising administering an effective amount of a pharmaceutical composition according to claim 23 to said subject.

59. (Withdrawn) The method of claim 58, wherein the subject is a human.

60. (Withdrawn) The method of claim 58, wherein the subject is an animal.

61. (Withdrawn) The method of claim 59, wherein the compound is selected from the group consisting of:



62. (Withdrawn) The method of claim 60, wherein the compound is selected from the group consisting of:



63. (Withdrawn) A method of inhibiting growth of invasive microbial cells in an animal or human subject comprising the administration of an effective amount of a pharmaceutical composition according to claim 23 to said subject.

64 - 65. (Cancelled)

66. (Withdrawn) The method of claim 64, wherein the compound is selected from the group consisting of:



67. (Withdrawn) The method of claim 65, wherein the compound is selected from the group consisting of:



68. (Not Entered)

69. (Currently Amended) Compounds according to claim 15, wherein

R^{21} = cycloalkyl, alkenyl, aryl, arylalkyl, or alkylaryl, $=CHR^{23}$, $-C(O)OR^{23}$ $-C(O)R^{23}$, $-CH_2C(O)OR^{23}$, $-CH_2C(O)NHR^{23}$, where R^{23} is H or C_1-C_{10} alkyl, cycloalkyl, or alkenyl, except when R^{21} is $=CHR^{23}$, R^{23} is not H ;

R^{22} = C_1-C_{20} alkyl, cycloalkyl, alkenyl, ~~aryl,~~ arylalkyl, or alkylaryl;

with the proviso that when R^{21} is -COOH, then R^{22} is not $\underline{-CH_3}$, $-C_{13}H_{27}$ $\underline{\text{or } C_{13}H_{27}}$ and with the further proviso that when R^{21} is $-CH_2COOH$, then R^{22} is not $-CH_2CH_3$, or $-iC_5H_{11}$.

70. (Previously Presented) A pharmaceutical composition comprising a pharmaceutical diluent and a compound according to claim 69.

71. (Previously Presented) Compounds of formula X:



X

wherein

R^{42} = C_2-C_{20} alkyl, cycloalkyl, alkenyl, aryl, arylalkyl, or alkylaryl.

72. (Previously Presented) A pharmaceutical composition comprising a pharmaceutical diluent and a compound according to claim 71.

73. (New) A method of inhibiting the activity of fatty acid synthase in a cell comprising administering to the cell an effective amount of a pharmaceutical composition comprising a pharmaceutical diluent and one or more compounds of formula V:



V

wherein

R^{21} = C_2-C_{20} alkyl, cycloalkyl, alkenyl, aryl, arylalkyl, or alkylaryl, =CHR^{23}, -$C(O)OR^{23}$ -$C(O)R^{23}$, -$CH_2C(O)OR^{23}$, -$CH_2C(O)NHR^{23}$, where R^{23} is H or C_1-C_{10} alkyl, cycloalkyl, or alkenyl; and

R^{22} = C_2-C_{20} alkyl, cycloalkyl, alkenyl, aryl, arylalkyl, or alkylaryl.